Skip to content
ClinicalJune 30, 2026· 8 min read

The lean mass problem is becoming a contracting issue

Body composition during rapid weight loss has moved from a clinical footnote to something buyers are starting to write into agreements.

M
MyGLP Research
Editorially independent · no vendor funding

Not all weight loss is equivalent

Rapid weight reduction carries a meaningful loss of lean mass alongside fat mass. In older members and those with lower baseline muscle, that shift carries real consequences for metabolic rate, functional capacity, and the likelihood of regain after discontinuation.

A program reporting excellent average weight loss while quietly degrading body composition in its most vulnerable members is not producing the outcome the buyer thinks it purchased.

What good vendors are doing

Protein targets set and monitored throughout titration rather than mentioned once at intake. Structured resistance training as a required program component, not an optional content library. Body composition measurement at defined intervals where practical. And age-stratified protocols that treat a 58-year-old differently from a 34-year-old.

The gap between vendors that do these things and vendors that mention them in marketing is wide, and it is visible in about ten minutes of specific questioning.

Getting it into the contract

Buyers are beginning to require reporting on body composition or a validated proxy, and to include resistance-training engagement in the definition of program engagement rather than counting app logins.

This is early, and the measurement infrastructure is genuinely immature. But asking the question during evaluation sorts vendors quickly, and it signals that you are evaluating the quality of the outcome rather than only its magnitude.

Evaluating vendors this cycle?

Our vendor directory scores every major player on the same six dimensions, with the commercial terms laid out side by side.

More insights

Pricing

The compounded GLP-1 cliff and what it did to vendor pricing

When compounded semaglutide access narrowed, the vendors built on it had to re-price. Here is who absorbed it and who passed it through.

Clinical

Persistence, not weight loss, is the metric that decides your ROI

Every vendor leads with average weight reduction. The number that actually determines whether your spend produced anything is how many members are still on therapy at month twelve.

Market

Point solution fatigue is reshaping how GLP-1 vendors get bought

Benefits teams running a dozen vendors are consolidating. That changes which GLP-1 vendors win, and it is not always the best clinical one.